Aptose Biosciences Inc. publishes significant preclinical data on tuspetinib, a new therapy for acute myeloid leukemia.
Dec 12, 2024
San DiegoBiotechnologyHealth CareMedicalTherapeuticsresearch
Product Description
Aptose announces the publication of preclinical data for its lead compound tuspetinib, showing its unique mechanism of action against AML cells, especially in combination with venetoclax. The findings reveal tuspetinib’s enhanced activity and safety profile, supporting its ongoing clinical development.
Company Information
Company
Aptose Biosciences
Location
12770 High Bluff Dr
San Diego, California, United States
About
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies.
Fundz sees it the moment Aptose Biosciences ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoBiotechnologyHealth CareMedicalTherapeuticsresearch